Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00006982-200506000-00023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial.
Lancet Oncol
December 2024
Department of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence, Florence, Italy; Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
Background: Optimal therapy following breast-conserving surgery in older adults with low-risk, early-stage breast cancer remains uncertain. The EUROPA trial aims to compare the effects of radiotherapy and endocrine therapy as single-modality treatments on health-related quality of life (HRQOL) and ipsilateral breast tumour recurrence (IBTR) outcomes in this population.
Methods: This non-inferiority, phase 3, randomised study was conducted at 18 academic hospitals across Italy (17 centres) and Slovenia (one centre).
Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial.
J Natl Cancer Inst
December 2024
Department of Oncology and Pathology, Karolinska Institutet, 171 64 Stockholm, Sweden.
Background: Estrogen receptor-positive breast cancer patients have a long-term risk of distant metastatic disease, and premenopausal patients have a higher risk. Randomized studies with long-term follow-up are essential to understand treatment benefit. We elucidated the long-term tamoxifen therapy benefit by menopausal status in the Stockholm tamoxifen trials with 20 years complete follow-up.
View Article and Find Full Text PDFFirst-line endocrine therapy combined with CDK 4/6 inhibitor in disseminated carcinomatosis of bone marrow (DCBM) luminal breast cancer: a case report.
J Med Case Rep
December 2024
Hematology Medical Oncology Division, Faculty of Medicine, Diponegoro University/Dr. Kariadi General Hospital Semarang, Semarang, Indonesia.
Article Synopsis
- - Metastatic breast cancer, particularly disseminated carcinomatosis of bone marrow (DCBM), is rare and poses a serious threat to life, with a focus on managing symptoms and improving quality of life rather than finding a cure.
- - A case study is presented of a 36-year-old woman diagnosed with luminal breast cancer who experienced severe symptoms due to DCBM; she was initially treated with tamoxifen but later switched to letrozole, ribociclib, and leuprorelin due to side effects.
- - The treatment adjustment led to significant improvements in her blood markers, symptoms, and overall quality of life, suggesting that combining endocrine therapy with a CDK4/6 inhibitor could be an effective
Idiopathic encapsulating peritoneal sclerosis: A case report.
Int J Surg Case Rep
November 2024
B Surgery Department, Charles Nicolle Hospital, Tunis, Tunisia.
Article Synopsis
- Encapsulating peritoneal sclerosis (EPS) is a rare condition that can present symptoms similar to other diseases, often leading to misdiagnosis; in this case, it was confused with an internal hernia.
- A 52-year-old male experienced abdominal pain and bloating for six months, and imaging suggested an internal hernia, but surgery revealed EPS with fibrous tissue encasing the bowel.
- EPS symptoms are caused by a thick capsule around the intestines, typically linked to peritoneal dialysis or inflammatory disorders, and treatment varies from managing underlying causes to surgical interventions, which carry risks of recurrence and high mortality.
Selecting the Right Dose to Move Breast Cancer Prevention Forward.
Cancer Prev Res (Phila)
December 2024
Division of Medical Oncology, Department of Medicine, E.O. Ospedali Galliera, Genoa, Italy.
Article Synopsis
- Low uptake and adherence to breast cancer preventive therapy are primarily due to fears of serious side effects and menopausal symptoms.
- A study indicates that low-dose tamoxifen is effective and has fewer side effects for high-risk women, leading to better patient adherence.
- More than 70% of women who were counseled about low-dose tamoxifen continued taking it after one year, suggesting this treatment could improve breast cancer prevention efforts and lower related mortality rates.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!